Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Judge

Showing results (171-180 of 260) with videos related to

Pageof 26
Sort By:
Heart Rhythm|July 3, 2013
Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entityAnneline S J M te Riele, Cynthia A James, Aditya Bhonsale, et al.
Cardiovascular Drugs and Therapy|February 17, 2020
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
American Journal of Human Genetics|February 2, 2024
Using implementation science to evaluate a population-wide genomic screening program: Findings from the first 20,000 In Our DNA SC participantsCaitlin G Allen, Kelly J Hunt, Lori L McMahon, et al.
European Journal of Heart Failure|March 2, 2026
Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: Observations from ATTRibute-CMFrancesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathyA Dénise den Haan, Boon Yew Tan, Michelle N Zikusoka, et al.
Circulation. Heart Failure|October 28, 2024
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) SubstudyYousuf Razvi, Daniel P Judge, Ana Martinez-Naharro, et al.
Cardiovascular Drugs and Therapy|June 18, 2020
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Nature Medicine|January 24, 2007
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic statesRonald D Cohn, Christel van Erp, Jennifer P Habashi, et al.
Journal of Cardiovascular Development and Disease|January 29, 2016
Targeted <i>Mybpc3</i> Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve AbnormalitiesDaniel P Judge, Hany Neamatalla, Russell A Norris, et al.
Journal of Personalized Medicine|August 26, 2022
Lessons Learned from the Pilot Phase of a Population-Wide Genomic Screening Program: Building the Base to Reach a Diverse Cohort of 100,000 ParticipantsCaitlin G Allen, Leslie Lenert, Kelly Hunt, et al.
Pageof 26

Showing results (171-180 of 260) with videos related to

Sort By:
Pageof 26
Heart Rhythm|July 3, 2013
Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entityAnneline S J M te Riele, Cynthia A James, Aditya Bhonsale, et al.
Cardiovascular Drugs and Therapy|February 17, 2020
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
American Journal of Human Genetics|February 2, 2024
Using implementation science to evaluate a population-wide genomic screening program: Findings from the first 20,000 In Our DNA SC participantsCaitlin G Allen, Kelly J Hunt, Lori L McMahon, et al.
European Journal of Heart Failure|March 2, 2026
Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: Observations from ATTRibute-CMFrancesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathyA Dénise den Haan, Boon Yew Tan, Michelle N Zikusoka, et al.
Circulation. Heart Failure|October 28, 2024
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) SubstudyYousuf Razvi, Daniel P Judge, Ana Martinez-Naharro, et al.
Cardiovascular Drugs and Therapy|June 18, 2020
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Nature Medicine|January 24, 2007
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic statesRonald D Cohn, Christel van Erp, Jennifer P Habashi, et al.
Journal of Cardiovascular Development and Disease|January 29, 2016
Targeted <i>Mybpc3</i> Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve AbnormalitiesDaniel P Judge, Hany Neamatalla, Russell A Norris, et al.
Journal of Personalized Medicine|August 26, 2022
Lessons Learned from the Pilot Phase of a Population-Wide Genomic Screening Program: Building the Base to Reach a Diverse Cohort of 100,000 ParticipantsCaitlin G Allen, Leslie Lenert, Kelly Hunt, et al.
Pageof 26